ReviewInternational journal of molecular sciences2017
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches.Biomarker research · 2025Review
- Article
- Research progress on recombinant NDV in cancer therapy.Frontiers in immunology · 2025Review
- Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.Journal of cellular and molecular medicine · 2024Article
- Progress on angiogenic and antiangiogenic agents in the tumor microenvironment.Frontiers in oncology · 2024Review
- Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.Cell death & disease · 2023Review
- Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines.Pharmaceutics · 2023Review
- Multicellular network analysis of melanoma heterogeneity by scRNA-seq.American journal of translational research · 2023Article
- Tumor endothelial cell-induced CD8Cancer science · 2022Article
- Co-culture of peripheral blood mononuclear cell (PBMC) and human coronary artery endothelial cell (HCAEC) reveals the important role of autophagy implicated in Kawasaki disease.Translational pediatrics · 2021Article
- Antigenic Essence: Upgrade of Cellular Cancer Vaccines.Cancers · 2021Review
- Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.Frontiers in cell and developmental biology · 2021Review
- Nanobodies as Versatile Tool for Multiscale Imaging Modalities.Biomolecules · 2020Review
- In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.Biotechnology and bioengineering · 2020Article
- A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside.HNO · 2020Review
- Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives.Frontiers in cell and developmental biology · 2020Review
- Engineering Targeting Materials for Therapeutic Cancer Vaccines.Frontiers in bioengineering and biotechnology · 2020Review
- SANTAVACVaccines · 2019Review
- Theranostics in immuno-oncology using nanobody derivatives.Theranostics · 2019Review
- The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy.The British journal of radiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor endothelial cells regulate several aspects of tumor biology, from delivering oxygen and nutrients to shaping the immune response against a tumor and providing a barrier against tumor cell dissemination. Accordingly, targeting tumor endothelial cells represents an important modality in cancer therapy. Whereas initial anti-angiogenic treatments focused mainly on blocking the formation of new blood vessels in cancer, emerging strategies are specifically influencing certain aspects of tumor endothelial cells. For instance, efforts are generated to normalize tumor blood vessels in order to improve tumor perfusion and ameliorate the outcome of chemo-, radio-, and immunotherapy. In addition, treatment options that enhance the properties of tumor blood vessels that support a host's anti-tumor immune response are being explored. Hence, upcoming anti-angiogenic strategies will shape some specific aspects of the tumor blood vessels that are no longer limited to abrogating angiogenesis. In this review, we enumerate approaches that target tumor endothelial cells to provide anti-cancer benefits and discuss their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.